Safety Evaluation of ExAblate MRgFUS for Prostate Cancer

NCT ID: NCT00811265

Last Updated: 2016-03-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-01-31

Study Completion Date

2013-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluate the safety, compatibility and imaging quality of the ExAblate MRgFUS system.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of this study is to evaluate safety, compatibility and imaging quality of the ExAblate MRgFUS system for prostate cancer, under simulated use conditions. No acoustic energy will be delivered and no focused ultrasound therapy will be performed. This is an imaging only study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Simulated ExAblate MRgFUS

Patients undergoing simulated ExAblate MRgFUS device use

Group Type EXPERIMENTAL

ExAblate MRgFUS for prostate cancer

Intervention Type DEVICE

Simulated use of ExAblate MRgFUS system

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ExAblate MRgFUS for prostate cancer

Simulated use of ExAblate MRgFUS system

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age of patients: up to 75 years.
* Men scheduled for radical prostatectomy due to prostate cancer.
* Patients who are able and willing to give consent and able to attend all study visits.

Exclusion Criteria

* Contraindications to MRI including: claustrophobia, weight over 120 kg, implanted ferromagnetic materials or foreign objects, and known intolerance to the MRI contrast agent (e.g. Gadolinium or Magnevist)
* Severely abnormal coagulation (INR\>1.5)
* Patients with unstable cardiac status including: unstable angina pectoris on medication, patients with documented myocardial infarction within six months of protocol entry, congestive heart failure requiring medication (other than diuretic), patients on anti-arrhythmic drugs, severe hypertension (diastolic BP \> 100 on medication), and patients with cardiac pacemakers
* Severe cerebrovascular disease (multiple CVA or CVA within 6 months)
* Individuals who are not able or willing to tolerate the required prolonged stationary supine position during imaging (approximately 1 hrs.)
* Any rectal pathology preventing probe insertion, (as active proctitis, ulcerative colitis, fissure ani, diverticulitis, previous rectal surgery, IBD, etc…)
* Any spinal pathology that prohibits maintaining supine position for more then an hour
* Any previous radiation to the pelvis.
Maximum Eligible Age

75 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

InSightec

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sheba Medical Center

Tel Litwinsky, , Israel

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Israel

Related Links

Access external resources that provide additional context or updates about the study.

http://www.insightec.com

Web page of clinical study Sponsor

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PC001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Characterization of Prostate Cancer With 3T MR
NCT00831142 ACTIVE_NOT_RECRUITING
68Ga-NTA-476 Imaging in Prostate Cancer
NCT06520449 COMPLETED EARLY_PHASE1